Ocular surface strategies are a must for treating patients with glaucoma

Article

As a chronic disease, glaucoma requires long-term, lifetime treatment, often with multiple ophthalmic medications.

The prevalence of ocular surface disease (OSD) is high in glaucoma patients.1 A number of factors-including increased age and medications typically taken by seniors, such as antihypertensives, antidepressants, and antihistamines-can cause dry eye symptoms and OSD. Additionally, repeated exposure to certain preservatives used in glaucoma medications can exacerbate this condition.

In a study of 630 glaucoma or ocular hypertension patients on topical IOP-lowering medications, nearly half had OSD index scores reflecting at least mild OSD symptoms; more than a quarter were classified as having moderate or severe OSD.2

BAK toxicity

Although benzalkonium chloride (BAK) does a remarkable job of keeping multi-dose eye drops sterile, animal experiments and clinical studies have shown that BAK can have dose-dependent toxic effects, compromising tear film stability and causing irritation to the cornea and conjunctiva. These ocular side effects may cause symptoms such as stinging, burning, and dryness.1,4

Considerable evidence also shows that preservatives can compromise the integrity of the tear film through their detergent effect on the lipid layer. This reduces tear film stability, causing excessive evaporation and resulting in increased ocular dryness.5,6,7 An impaired tear film can predispose the eye to inflammation and conjunctival metaplasia.

In addition, preservatives can affect the goblet cells by reducing their number and production of the protective mucin layer.8 Other effects of excessive preservative use include conjunctival epithelium inflammation and subconjunctival fibrosis.1

The side effects associated with long-term use of preserved anti-glaucoma medications can also adversely impact patient compliance with therapy and the likelihood of successful treatment.9

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
ODs reflect on their time in Minneapolis, Minnesota, citing continuing education, tech updates, and networking opportunities as valued takeaways from the meeting.
Nora Lee Cothran, OD, FAAO, discussed the importance of optometrists addressing mental health with patients in their chair.
Nora Lee Cothran, OD, FAAO, moderated an Innovation Hub panel that featured 3 companies, giving insights into what's to come in the optometric industry.
Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.
Marc Bloomenstein, OD, FAAO, is a clinical investigator in the trials and overviews the transformative potential of LNZ100.
Shawn Hobbs, OD, previews the annual NOA convention, which takes place in Columbus, Ohio, from July 10 to 12, 2025.
Clark Chang, OD, MSA, MSc, FAAO, gave a presentation alongside Susan Gromacki, OD, MS, FAAO, FSLS, at this year's Optometry's Meeting.
Selina McGee, OD, FAAO, Dipl ABO, shares key takeaways and a personal anecdote relating to the State of Dry Eye survey results.
Devin Sasser, OD, shares his excitement for Acuvue Oasys MAX 1-Day multifocal for astigmatism, the first and only daily disposable multifocal toric contact lens.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO.
© 2025 MJH Life Sciences

All rights reserved.